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Background: Complete revascularization (CR) of hemodynamically stable STEMI
improves outcomes when compared to culprit-only PCI. However, the optimal timing for
CR (CR during index PCI [iCR] versus staged PCI [sCR]) is unknown. sCR is defined as
revascularization of non-culprit lesions not done during the index procedure (mean 31.5±24.6
days after STEMI). Our goal was to determine whether iCR was the superior strategy when
compared to sCR.
Methods: A systematic review of Medline, Cochrane, and Embase was performed for RCTs
reporting outcomes of stable STEMI patients who had undergone CR. Only RCTs with
a clearly defined timing of CR, for the classification into iCR and sCR, and a follow-up of at
least 12 months were included. Seven RCTs comprising 6647 patients (mean age:62.9±1.4
years, male sex:79.4%) met these criteria and were included.
Results: After a mean follow-up of 25.1±9.4 months, iCR was associated with a significant
reduction in cardiovascular mortality (risk ratio [RR] 0.48, 95% confidence interval [CI]
0.26–0.90, p=0.02, relative risk reduction [RRR] 52%) and non-fatal reinfarctions (RR 0.42,
95% CI 0.25–0.70, p=0.001, RRR: 58%). sCR showed a significant reduction in non-fatal
reinfarctions only (RR 0.68, 95% CI 0.54–0.85, p=0.0008, RRR: 32%). There was no
difference in the safety outcome of contrast-induced nephropathy between groups.
Conclusion: iCR of stable STEMI patients is associated with a significant reduction in
cardiovascular death and a trend towards reduction in all-cause mortality. These benefits are
not seen in sCR. Both strategies are associated with a reduction in non-fatal reinfarctions.
Keywords: ST-segment elevation myocardial infarction, STEMI, percutaneous coronary
intervention, PCI, staged revascularization, complete revascularization.
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Percutaneous coronary intervention (PCI) is the treatment of choice for ST-elevation
myocardial infarction (STEMI), receiving a class I, Level of Evidence (LOE): A,
recommendation in the 2013 ACCF/AHA guidelines for the management of STelevation myocardial infarction.1 Around 50% of patients presenting with STEMI
have multivessel coronary artery disease (MVCAD), defined as ≥50% stenosis in
a non-culprit coronary artery during index angiography.2 MVCAD in patients with
STEMI carries a higher MACE risk than single vessel disease and as a result, many
RCT’s have focused on whether treatment of non-culprit lesions is beneficial.
International Journal of General Medicine 2021:14 2239–2248
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The 2013 guidelines, which gave a class III LOE
B indication (meaning harm) to primary PCI of non-culprit
MVCAD in stable STEMI patients, were derived from lim
ited, and often conflicting, data.1 The subsequent publication
of several randomized control trials (RCT) showed that com
plete revascularization (CR) of MVCAD in stable STEMI
patients, either during index PCI (iCR) or as a staged proce
dure (sCR), might improve outcomes.3–5 This prompted
a reassessment of the 2013 guidelines.
This process culminated with the publication of the 2015
ACC/AHA/SCAI Focused Update on Primary Percutaneous
Coronary Intervention for Patients With ST-Elevation
Myocardial Infarction, where CR was changed from a class
III recommendation (harm) to a class IIb LOE B-R (moderate
quality evidence from 1 or more RCTs).6
However, there was still hesitancy in adopting these guide
lines into clinical practice due to the relatively small number of
patients enrolled in previous RCTs, the lack of single hard
outcomes reaching statistical significance (dependence on
composite outcomes), and the absence of a recommendation
on the exact timing of CR (iCR vs sCR). A recently published,
large multicenter RCT, the COMPLETE trial (Complete
Revascularization with Multivessel PCI for Myocardial
Infarction),7 enrolled 4041 patients with a median follow-up
of 3 years. It showed benefit in two coprimary composite
outcomes (first coprimary composite of cardiovascular (CV)
death or myocardial infarction (MI) (hazard ratio [HR] 0.74,
95% confidence interval [CI] 0.60–0.91, p=0.004), and second
coprimary composite outcome of cardiovascular (CV) death,
MI or ischemia-driven revascularization (HR 0.51, 95% CI
0.43–0.61, P<0.001) when CR strategy was performed.
However, this study also failed to show significant benefit
for CR with regards to individual hard outcomes of CV
death (HR 0.93, 95% CI 0.65–1.32) or all-cause mortality
(HR 0.91, 95% CI 0.69–1.20).7
A recent meta-analysis by Pavasini et al showed
a significant benefit of CR vs culprit-lesion only strategy in
CV death (HR 0.62, 95% CI 0.39–0.97, p=0.04) and repeat MI
(HR 0.65, 95% CI 0.53–0.80, p<0.0001) but failed to demon
strate a significant benefit in all-cause mortality (HR 0.81, 95%
CI 0.60–1.10, p=0.18).8 A previous meta-analysis and metaregression by Pasceri et al9 showed a significant total mortality
benefit in CR compared to culprit-lesion only revascularization
(Relative Risk [RR] 0.62, 95% CI 0.39–0.97). However, that
analysis included two RCTs (Hamza et al and HELP AMI)10,11
that are not generalizable due to a strict inclusion criteria
(Hamza et al with diabetic patients only),11 or outdated technol
ogy (HELP AMI with heparin-coated stents).10

2240

Powered by TCPDF (www.tcpdf.org)

https://doi.org/10.2147/IJGM.S308385

DovePress

Given the aforementioned lack of clarity regarding the
optimal timing for CR and its true effects on clinically
relevant outcomes, we decided to perform a systematic
review and meta-analysis of all available RCTs that met
our criteria to try to ascertain if the timing of CR (either
iCR or sCR when compared with a culprit-lesion only
strategy) had any impact on single, hard outcomes of allcause mortality, CV death or non-fatal reinfarction).
A secondary goal of this meta-analysis was to determine
if there were any differences in safety outcomes of con
trast-induced nephropathy between iCR and sCR.

Methods
The present meta-analysis was performed according to
Cochrane Collaboration and Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
statements.12 This meta-analysis was registered in
PROSPERO with registration number CRD42020155116.

Search Strategy
We searched PubMed, Embase, and Cochrane Central
Register of Clinical Trials (Cochrane Library, Issue 02,
2017) databases from January 2008 through
November 2020 to identify RCTs comparing a CR vs
culprit-lesion only strategy in stable patients presenting
with STEMI.
We used the following terms: (“complete revasculari
zation”) AND (“STEMI” OR “ST-elevation myocardial
infarction”). Language was restricted to papers in English
only. The reference lists of identified articles were also
exhaustively reviewed for additional sources.

Eligibility Criteria
Studies with the following characteristics were considered
eligible: (A) RCTs comparing CR vs culprit-lesion only in
stable patients with STEMI; (B) clearly identified the tim
ing of the CR strategy (either iCR or sCR); (C) compared
the event rates of all-cause mortality, CV death and nonfatal reinfarction between the two groups; (D) compared
the rates of strokes and CIN between groups; (F) had
a follow-up period of at least 12 months.
Case reports, editorials, reviews, non-randomized stu
dies and expert opinions were excluded from our analysis.
Abstracts presented in major international conferences that
have not been published as full papers were not considered
in our analysis.
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Primary Outcome and Composite Safety
Outcome
The primary outcomes of this study were (A) All-cause
mortality (B) CV death, and (C) non-fatal reinfarction. The
safety outcome was contrast-induced nephropathy (CIN).
CV death was defined as all deaths with a clear cardio
vascular or unknown cause. Reinfarction was defined using
the Fourth Universal Definition of Myocardial Infarction.13
CIN was defined as an elevation of serum creatinine of ≥25%
or ≥0.5 mg/dl (44 μmol/l) from baseline within 48 h.14

Data Extractions and Quality Appraisal
Two investigators (R.C.C.R and S.M.I.R.) independently
screened all titles, abstracts and manually searched the full
text versions of all relevant studies that fulfilled the inclusion
criteria. References of the retrieved articles were independently
reviewed for further identification of potentially relevant stu
dies. Disagreements were resolved by consensus after discus
sion (R.C.C.R and S.M.I.R.). We extracted characteristics of
each study including methodology and baseline patient char
acteristics, CV deaths, non-fatal reinfarction, stroke rate, and
CIN rate. If the abovementioned information was not readily
available in the written article, the principal investigator of that
particular study was contacted to supply pertinent information.

Quality Assessment

Cerrud-Rodriguez et al

performed in line with recommendations from the Cochrane
Collaboration and PRISMA guidelines, using Review Manager
(RevMan version 5.4, the Cochrane Collaboration, 2020).15
Heterogeneity was assessed using the I2 statistics, which is the
proportion of total variation observed among the studies attri
butable to differences between studies rather than sampling
error (chance). Data were summarized across groups using
the Mantel-Haenszel Risk Ratio (RR) Fixed-Effect model if
I2<25.16 We considered I2<25% as low and I2≥75% as high.
The Random-Effects Model was used if I2≥25%. Publication
bias was estimated visually by funnel plots.15

Results
A total of 204 studies were identified using the specified
search criteria (Figure 1). After evaluation of these studies
based on titles and abstracts, 10 RCTs were further ana
lyzed in their full-text version, 3 of which were excluded
to result in 7 RCTs that fulfilled all inclusion criteria.
These 7 RCTs incorporated a total of 6647 participants
(79.4% male, average age 62.9± 1.4 years, mean follow-up
period 25.1±9.4 months). Other RCTs were excluded due
to a lack of information relevant to our study questions,
narrow population (Hamza et al RCT of diabetic patients
only11 limiting generalizability, outdated technology that is
no longer routinely used (HELP-AMI) with its heparincoated stents),10 or because of insufficient follow-up (less
than 12 months).

The quality and reporting of the included RCTs were assessed
using the Cochrane Risk of Bias Tool.15 Six categories were
included in the analysis [A] Selection bias: systematic differences
between baseline characteristics of the groups that are compared;
[B] Performance bias: systematic differences between groups in
the care that is provided, or in exposure to factors other than the
interventions of interest; [C] Detection bias: systematic differ
ences between groups in how outcomes are determined. Blinding
of outcome assessors may reduce the risk that knowledge of
which intervention was received, rather than the intervention
itself, affects outcome measurement; [D] Attrition bias: systema
tic differences between groups due to withdrawals from a study.
Withdrawals from the study lead to incomplete outcome data; [E]
Reporting bias: systematic differences between reported and
unreported findings; [F] Other biases: other sources of bias that
are relevant only in certain circumstances. Quality of the included
RCTs was summarized visually.

Statistical Analysis
Descriptive statistics are presented as number of cases (n) for
dichotomous and categorical variables. Statistical analysis was

International Journal of General Medicine 2021:14

Figure 1 Study selection. Process of study selection.
Abbreviation: RCT, randomized control trial.
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Notes: COMPARE-ACUTE 2017: Fractional Flow Reserve–Guided Multivessel Angioplasty in Myocardial Infarction. COMPLETE 2019: Complete Revascularization with Multivessel PCI for Myocardial Infarction. CVLPRIT 2015:
Randomized Trial of Complete Versus Lesion-Only Revascularization in Patients Undergoing Primary Percutaneous Coronary Intervention for STEMI and Multivessel Disease. DANAMI-3-PRIMULTI 2015: Complete revascularization
versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomized controlled trial. Ghani 2012: Treatment of non-culprit
lesions detected during primary PCI: long-term follow-up of a randomized clinical trial. Politi 2009: A randomized trial of target-vessel versus multi-vessel revascularization in ST-elevation myocardial infarction: major adverse cardiac
events during long-term follow-up. PRAMI 2013: Randomized Trial of Preventive Angioplasty in Myocardial Infarction.
Abbreviations: NA, Not Applicable; RCT, randomized control trial; PCI, percutaneous coronary intervention; pCR, Complete Revascularization performed during the primary PCI; sCR, Complete Revascularization performed as a
staged procedure; MI, Myocardial Infarction; STEMI, ST-elevation myocardial infarction.
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Table 1 Baseline Characteristics of Included RCTs
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Characteristics of Included Studies
The baseline characteristics of the included trials are sum
marized in Table 1. Complete revascularization during
index PCI was undertaken in 744 participants (11.2%),
whereas CR was done as a staged procedure in 2475
participants (37.2%). Culprit-vessel only PCI was done
in 3430 participants (51.6%). The mean age was 62.9
±1.4 years; 79.4% were males. The mean follow-up period
was 25.1± 9.4 months.

Quality Assessment and Publication Bias
Funnel plots did not suggest publication bias for the
selected outcomes (Figure 2). All the RCTs included in
this meta-analysis had good methodological quality indi
cating “low risk of bias” (Figure 3).

Impact of Complete Revascularization on
All-Cause Mortality
There was a non-significant, but remarkable trend towards
an all-cause mortality benefit in the iCR group when

Cerrud-Rodriguez et al

compared with the culprit-only group: iCR (RR 0.63, 95%
CI 0.40–1.00, p=0.05). No significant difference was seen in
the sCR group when compared with the culprit-only group
(RR 0.92, 95% CI 0.57–1.49, p=0.75) (Figure 4).

Impact of Complete Revascularization on
Cardiovascular Mortality
There was a statistically significant reduction in cardiovas
cular mortality in the iCR group, when compared to the
culprit-lesion only group (RR 0.48, 95% CI 0.26–0.90,
p=0.02), with a relative risk reduction (RRR) of 52%
(Figure 5). There was no benefit seen in the sCR group
(RR 0.73, 95% CI 0.38–1.41, p=0.35).

Impact of Complete Revascularization on
Non-Fatal Reinfarction
We found a statistically significant reduction in non-fatal
reinfarctions in both complete revascularization groups,
regardless of timing, when compared with the culpritonly strategy. The iCR group (RR 0.42, 95% CI 0.25–0.70,

Figure 2 Funnel Plots – (A) all-cause mortality of complete revascularization during index PCI (B) cardiovascular mortality of staged complete revascularization (C)
reinfarction events of complete revascularization during index PCI (D) reinfarction events of complete revascularization during staged complete revascularization. Primary
complete revascularization: Revascularization done at the time of primary percutaneous catheter intervention (PCI). Staged complete revascularization: Revascularization
done at a different time than the primary PCI.
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only group: iCR (RR 0.67, 95% CI 0.16–2.82, p=0.58) and
sCR (RR 0.83, 95% CI 0.83–2.17, p=0.23) (Figure 7).
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Discussion

Figure 3 Risk of bias summary: review authors’ judgements about each risk of bias
item for each included study. COMPARE-ACUTE 2017: Fractional Flow Reserve–
Guided Multivessel Angioplasty in Myocardial Infarction. COMPLETE 2019:
Complete Revascularization with Multivessel PCI for Myocardial Infarction.
CVLPRIT 2015: Randomized Trial of Complete Versus Lesion-Only
Revascularization in Patients Undergoing Primary Percutaneous Coronary
Intervention for STEMI and Multivessel Disease. DANAMI-3-PRIMULTI 2015:
Complete revascularization versus treatment of the culprit lesion only in patients
with ST-segment elevation myocardial infarction and multivessel disease (DANAMI3—PRIMULTI): an open-label, randomized controlled trial. Ghani 2012: Treatment
of non-culprit lesions detected during primary PCI: long-term follow-up of
a randomized clinical trial. Politi 2009: A randomized trial of target-vessel versus
multi-vessel revascularization in ST-elevation myocardial infarction: major adverse
cardiac events during long-term follow-up. PRAMI 2013: Randomized Trial of
Preventive Angioplasty in Myocardial Infarction.

p=0.001), with a relative risk reduction (RRR) of 58%
(Figure 6), whereas the sCR group (RR 0.68, 95% CI
0.54–0.85, p=0.0008) with a RRR of 32%. In the sCR
cohort, the statistical weight of the COMPLETE trial is
responsible for the significant decrease in reinfarctions.

Safety Outcome of Contrast-Induced
Nephropathy
There was no significant difference in outcomes between the
complete revascularization groups and the culprit-lesion
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Complete revascularization of MVCAD in patients who
present with a hemodynamically stable STEMI has been
shown to be beneficial when compared with a culpritvessel only strategy in previously published metaanalyses.8,9 In a recently published meta-analysis by
Atti et al, complete revascularization was associated
with a significantly decreased reinfarction rate (RR
0.69, 95% CI 0.50–0.95) and repeat revascularization
(RR 0.34, 95% CI 0.25–0.44) with no benefit in the
other studied efficacy outcomes (all-cause mortality and
cardiovascular mortality).17 However, the vast majority
of the previous meta-analyses pooled together data from
papers and populations that underwent complete revas
cularization during the index PCI as well as those who
did so as a staged procedure after the culprit lesion was
treated, without distinction regarding timing.
We performed this meta-analysis to determine whether
the timing of CR (iCR vs sCR), has an impact on cardio
vascular mortality, non-fatal reinfarction, and all-cause
mortality. With our findings, we have demonstrated that
iCR is superior to sCR because it lowers CV mortality and
shows a beneficial, yet non-significant trend in all-cause
mortality, when compared to culprit-only revascularization
in stable patients presenting with STEMI. This is impor
tant and relevant for a number of reasons.
Firstly, it challenges current day practice in which sCR
is more commonly performed than iCR. In a large cohort
study by Secemsky et al using the National Cardiovascular
Data Registry CathPCI Registry from the third quarter of
2009 to the first quarter of 2018,18 multivessel PCI was
performed in n=138,380 STEMI patients. Of these, 30.8%
(n=42,629) had multivessel PCI performed during the
index procedure, 31.6% (n=43,696) were done as staged
procedures during the index admission and 37.6%
(n=52,055) had multivessel PCI done within 45 days of
discharge.18 The same fact can be observed in our metaanalysis, where 77% of the patients underwent a staged
complete revascularization while only 23% underwent
complete revascularization during the index PCI.
sCR is likely popular because high quality data regard
ing the optimal timing does not exist at this time, as even
a recent review article by Bossard and Mehta puts in
evidence – the interventional community agrees on the

International Journal of General Medicine 2021:14
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Figure 4 Forest Plot – all-cause mortality (A) complete revascularization during index PCI (B) staged complete revascularization. Diamond indicates overall summary
estimate for the analysis (width of the diamond represents the 95% CI); width of the shaded square, size of the population. Fixed-effect model was used for this outcome
during index PCI as I2<25; random effects model was used for the staged complete revascularization outcome given I2≥25.
Abbreviations: CI, confidence interval; MH, Mantel–Haenszel; Complete: complete revascularization strategy; Culprit-only, culprit-only revascularization strategy; PCI,
percutaneous coronary intervention; iCR, complete revascularization during index PCI; sCR, staged complete revascularization.

Figure 5 Forest Plot – cardiovascular mortality (A) complete revascularization during index PCI (B) staged complete revascularization. Diamond indicates overall summary
estimate for the analysis (width of the diamond represents the 95% CI); width of the shaded square, size of the population. Fixed-effect model was used for this outcome
during index PCI as I2<25; random effects model was used for the staged complete revascularization outcome given I2≥25.
Abbreviations: CI, confidence interval; MH, Mantel–Haenszel; Complete, complete revascularization strategy; Culprit-only, culprit-only revascularization strategy; PCI,
percutaneous coronary intervention; iCR, complete revascularization during index PCI; sCR, staged complete revascularization.

benefits of performing a complete revascularization of this
patient population, but there is a lack of clear guidance
regarding the best timing.19 Also, performing a sCR vs
iCR is believed in routine clinical practice to lower the risk
of CIN, a belief that is refuted by the findings of our
metanalysis, which showed that no significant difference
exists in CIN between the two strategies.

International Journal of General Medicine 2021:14

Next, our analysis shows a trend towards benefit in allcause mortality when iCR is compared to culprit only (RR
0.63, 95% CI 0.40–1.00, p=0.05) which is not seen when
sCR was compared to culprit only (RR 0.92, 95% CI
0.57–1.49, p=0.75). To date, no RCT has ever shown an
all-cause mortality benefit with complete revasculariza
tion, possibly because no trials have previously been
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Figure 6 Forest Plot – non-fatal reinfarction (A) complete revascularization during index PCI (B) staged complete revascularization. Diamond indicates overall summary
estimate for the analysis (width of the diamond represents the 95% CI); width of the shaded square, size of the population. Fixed-effect model was used in both outcomes as
I2<25.
Abbreviations: CI, confidence interval; MH, Mantel–Haenszel; Complete, complete revascularization strategy; Culprit-only, culprit-only revascularization strategy; PCI,
percutaneous coronary intervention; iCR, complete revascularization during index PCI; sCR, staged complete revascularization.

Figure 7 Forest Plot –safety outcome of contrast-induced nephropathy (A) complete revascularization during Index PCI (B) staged complete revascularization. Diamond
indicates overall summary estimate for the analysis (width of the diamond represents the 95% CI); width of the shaded square, size of the population. Fixed-effect model was
used in both outcomes as I2<25.
Abbreviations: CI, confidence interval; MH, Mantel–Haenszel; Complete, complete revascularization strategy; Culprit-only, culprit-only revascularization strategy; PCI,
percutaneous coronary intervention.

powered to detect this difference. The CR arm in the
COMPLETE trial consisted only of sCR (acknowledged
by the authors as a limitation of the trial)7 and its results
were consistent with our meta-analysis as it failed to show
a benefit in CV mortality or all-cause mortality.7
Lastly, complete revascularization during the index PCI
has the potential to be more convenient for the patient, depend
ing on their clinical condition, and might even potentially
decrease healthcare costs. sCR is often done later during the
index hospitalization, which increases the length of stay and
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potentially further increases healthcare costs.20 Alternatively,
patients are discharged and electively readmitted for the sCR,
which can be inconvenient for the patient. Furthermore, this
can be challenging to coordinate if patients have poor socio
economic backgrounds or low health literacy.21
Our meta-analysis updates the findings presented by
Pasceri et al, which tried to ascertain the best timing of
complete revascularization to achieve optimal
outcomes.9 They used a composite outcome of death
and MI and determined that complete revascularization
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during index PCI was associated with a significant ben
efit in the primary composite outcome.9 A recent metaanalysis by Bainey et al22 compared the outcomes of
complete revascularization of STEMI patients compared
with a culprit-only strategy, showing significant benefit
in cardiovascular death (Odds Ratio [OR], 0.69 [95% CI,
0.48–0.99]; P = 0.05) and in the composite outcome of
cardiovascular death and new MI (OR, 0.69 [95% CI,
0.55–0.87]; P = 0.001). However, this paper did not
study the differences in outcomes between complete
revascularization during primary PCI vs complete revas
cularization as a staged procedure.22
The difference in CV death and mortality might be due to
the early occurrence of MACE events, many of which have
been found to occur within the first two to three weeks after
index revascularization.4 This period is often shorter than the
average time to sCR after the index PCI seen in clinical
practice. Another hypothesis is that the iCR can improve
perfusion to hibernating myocardium and areas of watershed
infarction sooner, leading to improved LV function and sub
sequently, improved clinical outcomes.23 Of note, a pilot
study assessing the usefulness of the SYNTAX II (SII) score
in patients presenting with a STEMI and cardiogenic shock
showed that SII was superior to SYNTAX score by using
a receiver-operator curve, with the 2 higher tertiles of SII
having a worse in-hospital mortality that the lower tertile.24
Despite the findings above that suggest iCR is superior,
we do identify one practical limitation in performing iCR:
catheterization lab schedule. There might be scenarios
where multiple emergent cases require the attention of
the interventionalist and from a real-world, cath lab logis
tics perspective it is simply more feasible to perform sCR.

Limitations
Our meta-analysis has several limitations: the included
studies had different inclusion and exclusion criteria, the
majority of the patients enrolled into the studies were
male, which might cause them to not represent the true
effect of either strategy on female sex patients, and race,
a strong predictor of severity of heart disease, with black
women faring particularly worse and suffering more
severe CAD than other sex and ethnic groups.25
Lastly, this meta-analysis included RCTs with hemo
dynamically stable patients only and these results cannot
be extrapolated to STEMI patients presenting with cardio
genic shock, who do not benefit from a iCR strategy.26
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Conclusion
Complete revascularization during index PCI of stable
STEMI patients is associated with a statistically significant
reduction in cardiovascular death and a non-significant
trend towards a reduction in all-cause mortality compared
to culprit-lesion-only revascularization, at 25.1±9.4
months follow-up. These benefits are not seen in staged
complete revascularization. Both strategies are associated
with a reduction in non-fatal reinfarctions and do not have
a significant difference in CIN rates. A RCT comparing
iCR to sCR with sufficient statistical power is needed to
confirm our findings.

Abbreviations
CI, confidence interval; RR, risk ratio; RRR, relative risk
reduction; STEMI, ST-segment elevation myocardial
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CAD, coronary artery disease; RCT, randomized control
trial.
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